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Abstract
Background: Carriage of Neisseria meningitidis occurs approximately in 10% of the population, onset of invasive
meningococcal disease (IMD) cannot be predicted and differs between ages. It remains unclear, which host factors
determine invasion of the bloodstream by the bacteria. Innate immunity has a very important role in the first recognition of
invading pathogens. The functional single nucleotide polymorphisms (SNPs) CD14 C-159T and toll-like receptor 4 (TLR4)
Asp299Gly have been associated with the risk of gram-negative infections. However, their role in development of IMD still
remains unclear. Our aim was to investigate the influence of CD14 C-159T and TLR4 Asp299Gly polymorphisms on the risk
of IMD.
Methodology/Principal Findings: It was a retrospective case control study. Surviving Austrian meningococcal disease
patients were enrolled by sending buccal swabs for DNA analysis. 185 cases with a proven meningococcal infection and 770
healthy controls were enrolled. In surviving meningococcal disease patients DNA analysis of CD14 C-159T and TLR 4
Asp299Gly polymorphisms was performed, as they are part of the innate immune response to bacterial determinants. CD14
C-159T and TLR4 Asp299Gly SNPs were not significantly associated with the presence of IMD when compared to healthy
controls. The odds ratio for CD14 C-159T SNP was 1.14 (95% confidence interval (CI) 0.91–1.43; p=0.266). In TLR4 Asp 299
Gly SNP the odds ratio was 0.78 (CI 0.47–1.43; p=0.359).
Conclusion/Significance: We could not observe a significant influence of CD14 C-159T and TLR4 Asp299Gly polymorphisms
on the risk of developing IMD in surviving meningococcal disease patients. To our knowledge, this is the first study
investigating the influence of the CD14 C-159T SNP on the susceptibility to IMD.
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Introduction
In the industrialized world invasive meningococcal disease
(IMD) remains a major cause of death and disability in children
and adolescent. IMD is a rare but dangerous infection with the
gram- negative bacterium Neisseria meningitides (N.meningitidis). The
disease is most common in young infants and children with a
smaller, secondary peak in adolescents. In contrast, carriage of N.
meningitidis is highest in adolescents (up to 30% university campus
e.g.) and lowest in young children (2–5%) [1–3]. Carriage of N.
meningitidis is mostly asymptomatic, especially in adolescents. The
understanding of the transmission process from carriage to disease
with N.meningitidis is crucial for the development of effective disease
control mechanism and to define a special patient risk profile.
Successful defence against N. meningitidis infection relies on an
innate immune response to bacterial determinants, such as
lipopolysaccharides (LPS) [4]. Cluster of differentiation (CD) 14
is a pattern recognition receptor playing an essential role in innate
immunity [5]. CD14 is found on the membrane of monocytes and
as a soluble form in serum [6–7]. Along with LPS-binding protein,
CD14 acts to transfer LPS (and other bacterial ligands) to the Toll-
like receptor 4 (TLR4)/MD-2 signalling complex. This results in
the activation of inflammatory gene expression.
Recent research indicates that there is significant individual
diversity in CD14/TLR4 mediated response. Therefore, a single
nucleotide polymorphism (SNP) in the TLR4 gene resulting in an
Asp to Gly substitution at codon 299 alters the extracellular
domain of the receptor, and airway epithelial cells of patients
carrying this polymorphism are hyporesponsive to LPS [8].
A polymorphism in the CD14 gene leads to a C-to-T change at
position 2159 in the proximal promoter region and was found to
be associated with increased CD14 expression [9]. Homozygous
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and membrane-bound CD14 [10–11]. Increased CD14 levels are
associated with inflammatory infectious diseases and poor
outcome in Gram-negative sepsis [12]. The variant may therefore
influence host recognition and clearance of bacteria. The impact
of CD14 C-159T SNP on the risk of gram-negative infections has
been investigated in several other studies [13–16]. However, the
influence of CD14 C-159T SNP on the risk of infection with N.
meningitidis and development of IMD has not been studied yet.
Only few reports exist investigating the relation between TLR4
Asp299Gly SNP and the susceptibility to IMD [17–18], but results
remain controversial.
Therefore, we conducted a case-control study to elucidate the
association of CD14 C-159T and TLR4 Asp299Gly SNPs on the
susceptibility to IMD. We wanted to know, if a genetically
determined deficiency in sensing meningococcal LPS increases risk
of disease.
Methods
Patients
The study was conducted as retrospective case-control study
involving 185 Caucasian patients (children, adolescent, and adults)
with confirmed diagnosis of IMD and 770 healthy controls.
Patients were notified to the Federal Office of Public Health or the
National Reference Centre for IMD in Austria during 1993 to
2004. IMD was defined as culture or detection by PCR of N.
meningitidis from blood or cerebrospinal fluid. We excluded patients
with clinical signs and symptoms of acute meningococcal infection
but negative cultures. Patients were invited by mail to participate
in the study. Cells for DNA-preparation were collected directly by
the patients using buccal swabs. Clinical, demographic and
laboratory data were collected in collaboration with the National
Reference Center for IMD in Austria. Age at disease onset,
gender, clinical picture of meningitis, sepsis or both, Glasgow
Outcome Scale and serotypes were recorded. DNA from 770
Caucasians, who participated as controls in the Multicentre
Allergy Study (MAS study), were used as reference controls [19].
The study was approved by the ethics committee of the Medical
University of Innsbruck and written informed consent was
obtained from each patient.
Genotyping
Genomic DNA was extracted from buccal swabs by standard-
ized techniques using the peqGOLDH Blood DNA Mini kit
(PEQLAB Biotechnologie Ltd., Erlangen, Germany). Reference
samples were previously genotyped for the CD14 C-159T SNP
[20] and were re-genotyped to avoid any methodical bias.
Genotyping was carried out by the 59 nuclease assay using
TaqManH MGB probes on an ABI PrismH 7000 Sequence
Detection System (Applied Biosystems, Forster City, CA).
TaqManH MGB probes were provided together with correspond-
ing PCR primers by the Assay-on-demand
TM service (Applied
Biosystems). Positive controls as well as non template controls were
included in each run. Genotypes were determined by SDS (version
1.1) software followed by a visual control of accurate genotype
classification.
Statistical analyses
The Chi-squared test and univariate logistic regression analysis
were used to evaluate the association between CD14 C-159T ,
TLR4 Asp299Gly and IMD. Statistical significance was defined as
a two-tailed p value ,0.05. Determined genotype frequencies
were tested for Hardy-Weinberg equilibrium by chi-square testing
with one degree of freedom. Statistical analyses were performed
with the software package SPSS 11.0 for Windows (SPSS, Inc.,
Chicago, IL, USA).
Statistical power analysis was performed using the PS program
(Dupont and Plummer, Jr., 1990). On the basis of published
frequency of the putative risk genotypes, i.e. homozygous for the
CD14 -159T allele (10) and heterozygous or homozygous for the
TLR4 299Gly allele (17), respectively, a priori power analysis
indicated that our study including 185 IMD cases and 770 controls
can provide a statistical power of 80% to demonstrate an odds
ratio (OR) of 1.68 and 1.88, respectively, for the association
between the risk genotypes and IMD at an alpha fault of 0.05.
Results
Patients
Patientsandcontrolsshowed a similargenderdistribution(52.2%
and 52.6% males within cases and controls, respectively). Age at
onset of IMD was widely scattered, ranging from 0.1 to 74 years
(Figure 1). Disease rate was highest in infants (below age of two
years) and declined during childhood. The number of cases
increased again in adolescents with a second peak in the age of 16
to 18 years. In adults (age.18 years) the prevalence of disease was
lower and rather stable. Clinical characteristics of patients were as
follows. State of health and immunocompetence were good in most
of the patients, comorbidity was rare, as this were mainly pediatric
patients. Most of the time meningococcal disease occurs in
previously healthy persons. Gender was equally distributed between
patients and controls. In surviving meningococcal disease patients
serogroup B was the most frequent serogroup (60.4%) followed by
serogroup C ( 36.7%) and others. The figure shows number of
patients and distribution of serogroup B and C in 2-year interval. In
young children serogroup B predominates, in contrast serogroupB
andCarealmost equalinadolescentandyoungadults.Sepsis (47%)
was more often seen in patients compared to meningitis (31.5%) or
mixed clinical picture (21.5%). The majority (78.3%) of our
surviving meningococcal disease patients had a Glasgow outcome
scale (GOS) of 5 (complete recovery), 15.1% had minor disability
(minor hearing loss), 6.6% displayed major disability (amputation of
limbs, major hearing or visual loss).
DNA analysis
Genotype frequencies of CD14 C-159T and TLR 4 Asp299Gly
are presented in table 1 and 2. All determined genotype
frequencies were under Hardy-Weinberg equilibrium. Table 1
presents data on genotype distribution of the CD14 C-159T and
TLR Asp299Gly SNP’s among patients with IMD and the control
group. Distribution did not significantly differ among IMD
patients and controls. To further address any associations between
SNPs and IMD we used different genetic models (dominant,
additive, and, if appropriate, recessive) (table 2). Neither CD14 C-
159T (OR 1.14; 95% CI 0.91–1.43; p=0.266) nor TLR4
Asp299Gly SNP (OR 0.78; 95% CI 0.47–1.43; p=0.359) was
significantly associated with the susceptibility to IMD in any
genetic model.
Discussion
This is the first time that data on CD14 C-159T SNP on the risk
of IMD are presented. Overall, CD14 C-159T and TLR4
Asp299Gly SNP were not significantly associated with the
prevalence of IMD in survivors. Data about genetic influence on
IMD are rare and controversial [21–22]. Our study presents data
in a large patient and control cohort.
SNPs and Meningococcal Disease
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negative infection has been examined in several studies providing
controversial results [13–16]. Sutherland provided data on CD14
and TLR 2 in patients with systemic inflammatory response
syndrome [16]. Rupp et al investigated CD14 SNP with
susceptibility to chronic Chlamydia pneumoniae infection [15],
and Agnese and Jessen found no association with CD14 SNP and
gram-negative infection [13,14]. However, no data have been
published investigating the influence of the CD14 C-159T SNP on
the susceptibility to IMD. This was unexpected, as CD14 plays an
essential role in innate immune response to bacterial lipopolysac-
charides (LPS) [4].
Only few reports exist investigating the relation between TLR4
Asp299Gly and susceptibility to IMD (17–18). Faber et al [17]
reported, that allele frequency was not higher in the overall patient
population (197 patients versus 214 controls), but a significantly
higher frequency was seen in 40 patients younger than 12 months
of age. As TLR4 is part of the innate immune response and a
mutation in this gene alters the extracellular domain of the
receptor, one would expect a higher susceptibility to IMD, if this
mutation is present. However, this was not seen in our patient
cohort with 185 IMD survivors when compared to 770 healthy
controls. This is also supported by Read et al [18], who also found
no association with susceptibility and severity of IMD in 1047
IMD patients when compared to 879 controls.
Meningococcal infection is a disease with a wide range of
clinical presentations and outcomes. Mortality is still high. With
such a clinical profile, it is important to elucidate genetic
determinants that may assist to attenuate its incidence or severity.
As reported earlier data on TLR4 Asp299Gly remain controver-
sial, our study gives negative results in a rather large patient and
control group.
Some limitations of our study should be reported. Since we have
chosen a retrospective case-control study design, we could not
collect genetic data of patients, who died from IMD, probably
leading to a certain genetic bias. It might well be that IMD is a
multifactorial event and the selected group of study participants
had survived because there was no difference to the control group.
With respect to this possibility, CD14 and TLR4 polymorphisms
could even have a positive effect on case fatality rate of IMD. In
contrast, Read and al [18] found no association with TLR4
sequence variant and severity of IMD in a large study cohort, as
mentioned above. Therefore, any genetic effects on disease
Table 1. Genotype distribution of the CD14 C-159T and TLR4
Asp299Gly variants among patients with meningococcal
disease compared to controls.
Genotype
SNP 1/1 1/2 2/2 p value
CD14 C-159T Patients 46 (24.9) 93 (50.3) 46 (24.9) 0.266
Controls 213 (27.7) 393 (51.0) 164 (21.3)
TLR4 Asp299Gly Patients 167 (90.3) 18 (9.7) 0 (0.0) 0.359
Controls 678 (88.2) 88 (11.4) 3 (0.4)
Data are numbers of subjects. Numbers in parentheses present percent values.
The frequent allele is denoted as ‘‘1’’ and the rare allele as ‘‘2’’. P values were
calculated with the Chi-squared test.
doi:10.1371/journal.pone.0007374.t001
Table 2. Associations between CD14 C-159T and TLR4
Asp299Gly variants with IMD using different genetic models.
SNP Model OR 95% CI P
Dominant 1.16 0.80–1.67 0.442
CD14 C-159T Recessive 1.22 0.84–1.78 0.294
Additive 1.14 0.91–1.43 0.266
TLR4 Asp299Gly Dominant 0.84 0.49–1.46 0.545
Additive 0.78 0.47–1.43 0.359
Odds ratios (OR) and 95% confidence intervals (CI) were obtained from
univariate logistic regression analysis. Due to minor allele frequency of the
299Gly allele of TLR4, no recessive genetic model was applied.
doi:10.1371/journal.pone.0007374.t002
Figure 1. Meningococcal disease, age of infection and serogroup distribution. Numbers of cases are plotted against age of infection,
presented as age groups in a 2-year interval, with respect to serogroups. Black bars indicate all cases, grey bars indicate serogroup B, and white bars
indicate serogroup C.
doi:10.1371/journal.pone.0007374.g001
SNPs and Meningococcal Disease
PLoS ONE | www.plosone.org 3 October 2009 | Volume 4 | Issue 10 | e7374severity remain debatable. It might well be that other single
nucleotide polymorphisms could play a significant role in the
susceptibility to IMD. However, we have chosen SNP CD14 C-
159T and TLR 4 Asp299Gly, as i) functional roles of these SNPs
have been described, altering gene expression and protein
function, respectively [8–11], and ii) the respective genes act
together and play important roles in innate immunity [5–7].
Nevertheless, we cannot exclude that other, probably rare
sequence variants in CD14 and TLR4 may exert causal effects
on the development of IMD, as this was previously described by
others [23].
We conclude that CD14 C-159T and TLR 4 Asp299Gly SNP’s
were not significantly associated with the prevalence in IMD
survivors. To our knowledge, this is the first study investigating the
influence of the CD14 C-159T SNP on the susceptibility to IMD.
Data are now required to confirm our findings.
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